DK1337527T3 - Indolylmaleinimidderivater som proteinkinase C-inhibitorer - Google Patents
Indolylmaleinimidderivater som proteinkinase C-inhibitorerInfo
- Publication number
- DK1337527T3 DK1337527T3 DK01993604T DK01993604T DK1337527T3 DK 1337527 T3 DK1337527 T3 DK 1337527T3 DK 01993604 T DK01993604 T DK 01993604T DK 01993604 T DK01993604 T DK 01993604T DK 1337527 T3 DK1337527 T3 DK 1337527T3
- Authority
- DK
- Denmark
- Prior art keywords
- indolylmaleinimide
- inhibitors
- derivatives
- protein kinase
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24640000P | 2000-11-07 | 2000-11-07 | |
US28370501P | 2001-04-13 | 2001-04-13 | |
PCT/EP2001/012785 WO2002038561A1 (en) | 2000-11-07 | 2001-11-05 | Indolylmaleimide derivatives as protein kinase c inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1337527T3 true DK1337527T3 (da) | 2010-01-04 |
Family
ID=26937956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01993604T DK1337527T3 (da) | 2000-11-07 | 2001-11-05 | Indolylmaleinimidderivater som proteinkinase C-inhibitorer |
Country Status (31)
Country | Link |
---|---|
EP (2) | EP1337527B1 (el) |
JP (1) | JP4234426B2 (el) |
KR (3) | KR100748386B1 (el) |
CN (1) | CN1253449C (el) |
AR (1) | AR035211A1 (el) |
AT (1) | ATE445613T1 (el) |
AU (3) | AU2181002A (el) |
BR (1) | BRPI0115193B1 (el) |
CA (1) | CA2428133C (el) |
CY (1) | CY1110564T1 (el) |
CZ (1) | CZ307144B6 (el) |
DE (1) | DE60140201D1 (el) |
DK (1) | DK1337527T3 (el) |
EC (1) | ECSP104578A (el) |
ES (1) | ES2332770T3 (el) |
HK (1) | HK1058789A1 (el) |
HU (1) | HU228999B1 (el) |
IL (3) | IL155618A0 (el) |
MX (1) | MXPA03004037A (el) |
MY (2) | MY139979A (el) |
NO (1) | NO327427B1 (el) |
NZ (2) | NZ535616A (el) |
PE (1) | PE20020544A1 (el) |
PL (1) | PL208794B1 (el) |
PT (1) | PT1337527E (el) |
RU (2) | RU2329263C2 (el) |
SG (1) | SG159378A1 (el) |
SI (1) | SI1337527T1 (el) |
SK (1) | SK287919B6 (el) |
TW (2) | TWI290553B (el) |
WO (1) | WO2002038561A1 (el) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
MXPA04012188A (es) | 2002-06-05 | 2005-07-25 | Johnson & Johnson | Derivados de bisindolil-maleimida como inhibidores de cinasa. |
US7232906B2 (en) | 2002-06-05 | 2007-06-19 | Janssen Pharmaceutica N.V. | Substituted pyrrolines as kinase inhibitors |
GB0303319D0 (en) | 2003-02-13 | 2003-03-19 | Novartis Ag | Organic compounds |
EP2228069A1 (en) * | 2003-09-16 | 2010-09-15 | Garvan Institute Of Medical Research | Antagonists of protein kinase c-epsilon (pkcepsilon) and their use for the treatment of aberrant glucose metabolism associated therewith. |
WO2005039549A1 (en) * | 2003-10-27 | 2005-05-06 | Novartis Ag | Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation |
AU2004289303A1 (en) * | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
ES2402298T3 (es) * | 2004-01-19 | 2013-04-30 | Novartis Ag | Derivados de indolilmaleimida como inhibidores del tratamiento de rechazo del injerto o enfermedades autoinmunes |
GB0401089D0 (en) * | 2004-01-19 | 2004-02-18 | Novartis Ag | Organic compounds |
EP1734952A1 (en) * | 2004-04-08 | 2006-12-27 | Novartis AG | Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection |
GB0410713D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
AU2005313485B2 (en) | 2004-12-08 | 2011-02-03 | Johannes Gutenberg-Universitat Mainz | 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors |
GB0504203D0 (en) * | 2005-03-01 | 2005-04-06 | Novartis Ag | Organic compounds |
GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
EP1885454A2 (en) | 2005-05-04 | 2008-02-13 | DeveloGen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
GB0511060D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
KR20080023732A (ko) * | 2005-07-11 | 2008-03-14 | 노파르티스 아게 | 인돌릴말레이미드 유도체 |
NO345888B1 (no) | 2005-10-26 | 2021-09-27 | Novartis Ag | Medikament til bruk ved behandling av familiær Middelhavsfeber omfattende et humant IL-1-beta bindende antistoff og en farmasøytisk sammensetning omfattende antistoffet til bruk ved behandling av familiær Middelhavsfeber. |
US9006224B2 (en) | 2005-11-21 | 2015-04-14 | Novartis Ag | Neuroendocrine tumor treatment |
GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
GB0613162D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic compounds |
JP2010501586A (ja) * | 2006-08-23 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 眼疾患におけるpkc阻害剤、特にインドリルマレイミド誘導体の使用 |
MX2009004048A (es) * | 2006-10-20 | 2009-04-27 | Novartis Ag | Modificaciones de cristal de la 3-(1h-indol-3-il)-4-[2-(4-metil-pi perazin-1-il)-quinazolin-4-il]-pirrol-2,5-diona. |
CA2671040A1 (en) * | 2006-12-07 | 2008-06-19 | Novartis Ag | Use of pkc inhibitors in transplantation |
AU2007336338A1 (en) | 2006-12-19 | 2008-06-26 | Novartis Ag | Indolylmaleimide derivatives as kinase inhibitors |
RU2487128C2 (ru) * | 2007-03-09 | 2013-07-10 | Новартис Аг | Соли 3-(1н-индол-3-ил)-4-[2-(4-метилпиперазин-1-ил)хиназолин-4-ил]пиррол-2,5-диона |
KR20160017119A (ko) | 2007-05-29 | 2016-02-15 | 노파르티스 아게 | 항-il-1-베타 치료법에 대한 신규 적응증 |
EP2198309A1 (en) * | 2007-09-27 | 2010-06-23 | Novartis Ag | Drug monitoring assay |
EP2209916B1 (en) | 2007-11-08 | 2011-12-21 | Novartis AG | Gene expression signatures for chronic/sclerosing allograft nephropathy |
JP5576290B2 (ja) | 2007-12-05 | 2014-08-20 | ヨハネス、グーテンベルク−ウニフェルジテート、マインツ | 白血病の管理における3−(インドリル)−または3−(アザインドリル)−4−アリールマレイミド誘導体の用途 |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
CA2767616A1 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
EP2338486A1 (en) | 2009-12-18 | 2011-06-29 | Johannes Gutenberg-Universität Mainz | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma |
EP2343291A1 (en) | 2009-12-18 | 2011-07-13 | Johannes Gutenberg-Universität Mainz | 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
US8791100B2 (en) | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
RU2012146083A (ru) | 2010-03-30 | 2014-05-10 | Новартис Аг | Ингибиторы ркс для лечения в-клеточной лимфомы с хроническими активным сигнальным каскадом в-клеточного рецептора |
UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
EP2474541A1 (en) | 2010-12-23 | 2012-07-11 | Johannes- Gutenberg-Universität Mainz | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
CN102153605B (zh) * | 2011-03-02 | 2014-02-19 | 福建省微生物研究所 | 一种咪唑立宾的提纯方法 |
UY34072A (es) | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
SG195067A1 (en) | 2011-06-27 | 2013-12-30 | Novartis Ag | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
GB201111427D0 (en) * | 2011-07-05 | 2011-08-17 | Amakem Nv | Novel bisindolylmaleimides, pan-pkc inhibitors |
CA2841111A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013057711A1 (en) | 2011-10-21 | 2013-04-25 | Novartis Ag | Quinazoline derivatives as pi3k modulators |
US20140348848A1 (en) | 2011-12-02 | 2014-11-27 | Dhananjay Kaul | Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease |
EA029473B1 (ru) | 2011-12-15 | 2018-03-30 | Новартис Аг | Применение ингибиторов pi3k для лечения острой и церебральной малярии |
EP2794594A1 (en) | 2011-12-22 | 2014-10-29 | Novartis AG | Quinoline derivatives |
SG11201402237WA (en) | 2011-12-22 | 2014-09-26 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
EP2847191B1 (en) | 2012-05-09 | 2016-06-15 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
AU2013343059A1 (en) | 2012-11-07 | 2015-04-09 | Novartis Ag | Substituted indole derivatives |
TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫-吡啶并-□衍生物之固體形式 |
NZ708802A (en) | 2012-11-29 | 2019-09-27 | Novartis Ag | Pharmaceutical combinations comprising a protein kinase c inhibitor compound and a mitogen activated protein kinase inhibitor compound |
JP2016508962A (ja) * | 2012-12-10 | 2016-03-24 | セントジーン アーゲー | ガンを予防および治療するためのマレイミド誘導体の使用 |
EP2928466B1 (en) * | 2012-12-10 | 2020-10-28 | Centogene GmbH | Use of maleimide derivatives for preventing and treating leukemia |
WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
SG11201600028YA (en) | 2013-09-22 | 2016-02-26 | Calitor Sciences Llc | Substituted aminopyrimidine compounds and methods of use |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
CA2943979A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
JP6404944B2 (ja) | 2014-04-24 | 2018-10-17 | ノバルティス アーゲー | ホスファチジルイノシトール3−キナーゼ阻害薬としてのピラジン誘導体 |
MX2016013981A (es) | 2014-04-24 | 2016-11-15 | Novartis Ag | Derivados de amino-piridina como inhibidores de fosfatidil-inositol-3-cinasa. |
CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
EP3146077A4 (en) | 2014-05-22 | 2018-05-02 | The Scripps Research Institute | Tissue molecular signatures of kidney transplant rejections |
US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
MX2018001903A (es) | 2015-08-14 | 2018-06-20 | Novartis Ag | Inhibidores de mdm2 para el tratamiento de melanoma uveal. |
US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
EP3187495A1 (en) | 2015-12-30 | 2017-07-05 | Johannes Gutenberg-Universität Mainz | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
SG11201806628UA (en) | 2016-02-03 | 2018-09-27 | Galderma Res & Dev | New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof |
WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
WO2018175340A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
US10683297B2 (en) | 2017-11-19 | 2020-06-16 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
CA3083040A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
CN110551103B (zh) * | 2018-05-30 | 2022-08-23 | 北京大学深圳研究生院 | 一种jak3选择性抑制剂 |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
JP2022534216A (ja) | 2019-05-23 | 2022-07-28 | ノバルティス アーゲー | Btk阻害剤の結晶形態 |
BR112022025381A2 (pt) | 2020-06-11 | 2023-01-24 | Provention Bio Inc | Métodos e composições para prevenir diabetes tipo 1 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4066674A (en) | 1975-11-12 | 1978-01-03 | Schering Aktiengesellschaft | Process for the preparation of 1,3-oxygenated 8α-estratrienes and novel intermediates obtained therefrom |
IL89167A (en) * | 1988-02-10 | 1994-02-27 | Hoffmann La Roche | Substituted pyrroles, their manufacture and pharmaceutical compositions containing them |
FR2637591B1 (fr) | 1988-10-11 | 1992-10-23 | Synthelabo | Derives de quinoleinone, leur preparation et leur application en therapeutique |
WO2000021927A2 (en) * | 1998-10-08 | 2000-04-20 | Smithkline Beecham Plc | Pyrrole-2,5-diones as gsk-3 inhibitors |
GB9828640D0 (en) * | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
PL366701A1 (en) * | 2000-07-27 | 2005-02-07 | F.Hoffmann-La Roche Ag | 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta |
-
2001
- 2001-11-05 MX MXPA03004037A patent/MXPA03004037A/es active IP Right Grant
- 2001-11-05 SI SI200130954T patent/SI1337527T1/sl unknown
- 2001-11-05 KR KR1020037005805A patent/KR100748386B1/ko not_active IP Right Cessation
- 2001-11-05 WO PCT/EP2001/012785 patent/WO2002038561A1/en active Application Filing
- 2001-11-05 PE PE2001001093A patent/PE20020544A1/es not_active Application Discontinuation
- 2001-11-05 AT AT01993604T patent/ATE445613T1/de active
- 2001-11-05 EP EP01993604A patent/EP1337527B1/en not_active Expired - Lifetime
- 2001-11-05 CA CA002428133A patent/CA2428133C/en not_active Expired - Fee Related
- 2001-11-05 AR ARP010105176A patent/AR035211A1/es not_active Application Discontinuation
- 2001-11-05 RU RU2003115429/04A patent/RU2329263C2/ru not_active IP Right Cessation
- 2001-11-05 NZ NZ535616A patent/NZ535616A/xx not_active IP Right Cessation
- 2001-11-05 DE DE60140201T patent/DE60140201D1/de not_active Expired - Lifetime
- 2001-11-05 AU AU2181002A patent/AU2181002A/xx active Pending
- 2001-11-05 HU HU0301651A patent/HU228999B1/hu not_active IP Right Cessation
- 2001-11-05 KR KR1020087002849A patent/KR20080014934A/ko not_active Application Discontinuation
- 2001-11-05 ES ES01993604T patent/ES2332770T3/es not_active Expired - Lifetime
- 2001-11-05 EP EP09151894A patent/EP2070921A1/en not_active Withdrawn
- 2001-11-05 PT PT01993604T patent/PT1337527E/pt unknown
- 2001-11-05 BR BRPI0115193A patent/BRPI0115193B1/pt not_active IP Right Cessation
- 2001-11-05 SK SK546-2003A patent/SK287919B6/sk not_active IP Right Cessation
- 2001-11-05 JP JP2002541095A patent/JP4234426B2/ja not_active Expired - Fee Related
- 2001-11-05 IL IL15561801A patent/IL155618A0/xx active IP Right Grant
- 2001-11-05 CZ CZ2003-1266A patent/CZ307144B6/cs not_active IP Right Cessation
- 2001-11-05 KR KR1020067017472A patent/KR100916613B1/ko not_active IP Right Cessation
- 2001-11-05 AU AU2002221810A patent/AU2002221810B2/en not_active Ceased
- 2001-11-05 PL PL361409A patent/PL208794B1/pl unknown
- 2001-11-05 DK DK01993604T patent/DK1337527T3/da active
- 2001-11-05 SG SG200502844-4A patent/SG159378A1/en unknown
- 2001-11-05 NZ NZ525656A patent/NZ525656A/xx not_active IP Right Cessation
- 2001-11-05 CN CNB018199925A patent/CN1253449C/zh not_active Expired - Fee Related
- 2001-11-06 MY MYPI20055681A patent/MY139979A/en unknown
- 2001-11-06 MY MYPI20015097A patent/MY127157A/en unknown
- 2001-11-07 TW TW090127656A patent/TWI290553B/zh not_active IP Right Cessation
- 2001-11-07 TW TW096118830A patent/TW200738687A/zh unknown
-
2003
- 2003-04-28 IL IL155618A patent/IL155618A/en not_active IP Right Cessation
- 2003-05-06 NO NO20032034A patent/NO327427B1/no not_active IP Right Cessation
-
2004
- 2004-01-14 HK HK04100271.6A patent/HK1058789A1/xx not_active IP Right Cessation
-
2005
- 2005-06-01 AU AU2005202387A patent/AU2005202387B2/en not_active Ceased
-
2007
- 2007-04-10 IL IL182428A patent/IL182428A0/en unknown
-
2008
- 2008-02-14 RU RU2008105345/04A patent/RU2008105345A/ru not_active Application Discontinuation
-
2009
- 2009-11-25 CY CY20091101228T patent/CY1110564T1/el unknown
-
2010
- 2010-03-11 EC EC2010004578A patent/ECSP104578A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1337527T3 (da) | Indolylmaleinimidderivater som proteinkinase C-inhibitorer | |
NO20031189L (no) | Pyrazolforbindelser nyttige som proteinkinaseinhibitorer | |
NO20032704L (no) | Pyrazolforbindelser nyttige som proteinkinaseinhibitorer | |
NO20021239D0 (no) | Pteridinoner som kinase-inhibitorer | |
NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
ID30460A (id) | Inhibitor-inhibitor protein siklik tirosin kinase | |
NO20023828L (no) | Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer | |
NO20030779L (no) | Kondenserte pyrazolderivater som er proteinkinase-inhibitorer | |
DK1650203T3 (da) | Quinolinonderivater som tyrosinkinaseinhibitorer | |
NO20011575D0 (no) | Substituerte 3-cyanokinoliner som proteintyrosin-kinase- inhibitorer | |
NO20011574L (no) | Substituerte 3-cyanokinoliner som proteintyrosin-kinsase- inhibitorer | |
DE60129794D1 (de) | Pyrrol substituierte indolin-2-on protein kinase inhibitoren | |
DK1140840T3 (da) | omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer | |
NO20030958D0 (no) | Pyrazolderivater og deres anvendelse som proteinkinase inhibitorer | |
DK1370554T3 (da) | 3-(4-Amidopyrrol-2-ylmethyliden)-2-indolinon-derivater som proteinkinaseinhibitorer | |
NO20035728L (no) | Pyrrolopyrimidiner som proteinkinaseinhibitorer | |
DK1690853T3 (da) | Omega-carboxyaryl-substituerede diphenylurinstoffer til anvendelse som raf-kinaseinhibitorer | |
DK1317448T4 (da) | Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer | |
DK1296981T3 (da) | Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer |